Intrinsic value of Amarin ADR - AMRN

Previous Close

$3.97

  Intrinsic Value

$2.00

stock screener

  Rating & Target

sell

-50%

Previous close

$3.97

 
Intrinsic value

$2.00

 
Up/down potential

-50%

 
Rating

sell

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of AMRN stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  58.54
  42.40
  38.66
  35.29
  32.26
  29.54
  27.08
  24.88
  22.89
  21.10
  19.49
  18.04
  16.74
  15.56
  14.51
  13.56
  12.70
  11.93
  11.24
  10.61
  10.05
  9.55
  9.09
  8.68
  8.31
  7.98
  7.68
  7.42
  7.17
  6.96
  6.76
Revenue, $m
  130
  185
  257
  347
  459
  595
  756
  944
  1,160
  1,405
  1,679
  1,982
  2,314
  2,674
  3,062
  3,477
  3,918
  4,386
  4,879
  5,396
  5,939
  6,506
  7,097
  7,714
  8,355
  9,022
  9,715
  10,436
  11,185
  11,963
  12,772
Variable operating expenses, $m
 
  81
  112
  152
  201
  261
  331
  414
  508
  615
  735
  868
  1,013
  1,171
  1,341
  1,523
  1,716
  1,921
  2,137
  2,364
  2,601
  2,850
  3,109
  3,379
  3,660
  3,952
  4,255
  4,571
  4,899
  5,240
  5,594
Fixed operating expenses, $m
 
  151
  154
  158
  162
  166
  170
  175
  179
  184
  188
  193
  198
  203
  208
  213
  218
  224
  229
  235
  241
  247
  253
  259
  266
  273
  279
  286
  293
  301
  308
Total operating expenses, $m
  196
  232
  266
  310
  363
  427
  501
  589
  687
  799
  923
  1,061
  1,211
  1,374
  1,549
  1,736
  1,934
  2,145
  2,366
  2,599
  2,842
  3,097
  3,362
  3,638
  3,926
  4,225
  4,534
  4,857
  5,192
  5,541
  5,902
Operating income, $m
  -66
  -47
  -10
  37
  96
  168
  254
  356
  473
  606
  755
  921
  1,103
  1,300
  1,513
  1,741
  1,984
  2,241
  2,513
  2,798
  3,097
  3,409
  3,736
  4,076
  4,430
  4,798
  5,181
  5,579
  5,992
  6,422
  6,869
EBITDA, $m
  -65
  -45
  -8
  40
  99
  173
  260
  363
  482
  617
  768
  936
  1,120
  1,321
  1,536
  1,768
  2,014
  2,275
  2,550
  2,839
  3,142
  3,459
  3,790
  4,135
  4,494
  4,867
  5,255
  5,659
  6,078
  6,514
  6,967
Interest expense (income), $m
  17
  8
  3
  6
  10
  15
  21
  28
  36
  46
  57
  69
  82
  97
  113
  130
  149
  168
  189
  211
  234
  258
  283
  310
  337
  366
  395
  426
  458
  491
  526
Earnings before tax, $m
  -76
  -55
  -13
  31
  86
  153
  234
  328
  437
  560
  699
  852
  1,020
  1,203
  1,400
  1,611
  1,835
  2,073
  2,323
  2,587
  2,863
  3,151
  3,452
  3,766
  4,093
  4,432
  4,785
  5,153
  5,534
  5,931
  6,343
Tax expense, $m
  10
  0
  0
  8
  23
  41
  63
  89
  118
  151
  189
  230
  275
  325
  378
  435
  495
  560
  627
  698
  773
  851
  932
  1,017
  1,105
  1,197
  1,292
  1,391
  1,494
  1,601
  1,713
Net income, $m
  -86
  -55
  -13
  23
  63
  112
  171
  239
  319
  409
  510
  622
  745
  878
  1,022
  1,176
  1,340
  1,513
  1,696
  1,888
  2,090
  2,300
  2,520
  2,749
  2,988
  3,236
  3,493
  3,761
  4,040
  4,330
  4,631

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  98
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  167
  98
  136
  184
  244
  316
  401
  501
  616
  746
  891
  1,052
  1,228
  1,419
  1,625
  1,845
  2,080
  2,328
  2,590
  2,864
  3,152
  3,453
  3,767
  4,094
  4,435
  4,789
  5,157
  5,539
  5,937
  6,350
  6,779
Adjusted assets (=assets-cash), $m
  69
  98
  136
  184
  244
  316
  401
  501
  616
  746
  891
  1,052
  1,228
  1,419
  1,625
  1,845
  2,080
  2,328
  2,590
  2,864
  3,152
  3,453
  3,767
  4,094
  4,435
  4,789
  5,157
  5,539
  5,937
  6,350
  6,779
Revenue / Adjusted assets
  1.884
  1.888
  1.890
  1.886
  1.881
  1.883
  1.885
  1.884
  1.883
  1.883
  1.884
  1.884
  1.884
  1.884
  1.884
  1.885
  1.884
  1.884
  1.884
  1.884
  1.884
  1.884
  1.884
  1.884
  1.884
  1.884
  1.884
  1.884
  1.884
  1.884
  1.884
Average production assets, $m
  9
  13
  18
  24
  32
  41
  52
  65
  80
  97
  116
  137
  160
  184
  211
  240
  270
  303
  337
  372
  410
  449
  490
  532
  576
  623
  670
  720
  772
  825
  881
Working capital, $m
  70
  4
  6
  8
  11
  14
  17
  22
  27
  32
  39
  46
  53
  61
  70
  80
  90
  101
  112
  124
  137
  150
  163
  177
  192
  208
  223
  240
  257
  275
  294
Total debt, $m
  116
  28
  63
  106
  159
  224
  301
  391
  494
  611
  742
  887
  1,045
  1,217
  1,403
  1,601
  1,812
  2,035
  2,271
  2,518
  2,777
  3,048
  3,330
  3,625
  3,931
  4,250
  4,581
  4,925
  5,283
  5,655
  6,041
Total liabilities, $m
  176
  88
  123
  166
  219
  284
  361
  451
  554
  671
  802
  947
  1,105
  1,277
  1,463
  1,661
  1,872
  2,095
  2,331
  2,578
  2,837
  3,108
  3,390
  3,685
  3,991
  4,310
  4,641
  4,985
  5,343
  5,715
  6,101
Total equity, $m
  -9
  10
  14
  18
  24
  32
  40
  50
  62
  75
  89
  105
  123
  142
  163
  185
  208
  233
  259
  286
  315
  345
  377
  409
  443
  479
  516
  554
  594
  635
  678
Total liabilities and equity, $m
  167
  98
  137
  184
  243
  316
  401
  501
  616
  746
  891
  1,052
  1,228
  1,419
  1,626
  1,846
  2,080
  2,328
  2,590
  2,864
  3,152
  3,453
  3,767
  4,094
  4,434
  4,789
  5,157
  5,539
  5,937
  6,350
  6,779
Debt-to-equity ratio
  -12.889
  2.890
  4.600
  5.750
  6.540
  7.100
  7.510
  7.800
  8.030
  8.200
  8.330
  8.430
  8.510
  8.580
  8.630
  8.670
  8.710
  8.740
  8.770
  8.790
  8.810
  8.830
  8.840
  8.850
  8.860
  8.870
  8.880
  8.890
  8.900
  8.910
  8.910
Adjusted equity ratio
  -1.551
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -86
  -55
  -13
  23
  63
  112
  171
  239
  319
  409
  510
  622
  745
  878
  1,022
  1,176
  1,340
  1,513
  1,696
  1,888
  2,090
  2,300
  2,520
  2,749
  2,988
  3,236
  3,493
  3,761
  4,040
  4,330
  4,631
Depreciation, amort., depletion, $m
  1
  1
  2
  3
  4
  5
  6
  7
  9
  11
  13
  15
  18
  20
  23
  27
  30
  34
  37
  41
  46
  50
  54
  59
  64
  69
  74
  80
  86
  92
  98
Funds from operations, $m
  -80
  -53
  -11
  25
  66
  116
  176
  247
  328
  420
  523
  637
  762
  899
  1,045
  1,202
  1,370
  1,547
  1,733
  1,930
  2,135
  2,350
  2,575
  2,808
  3,052
  3,305
  3,568
  3,841
  4,126
  4,421
  4,729
Change in working capital, $m
  -8
  1
  2
  2
  3
  3
  4
  4
  5
  6
  6
  7
  8
  8
  9
  10
  10
  11
  11
  12
  12
  13
  14
  14
  15
  15
  16
  17
  17
  18
  19
Cash from operations, $m
  -72
  -54
  -13
  23
  64
  113
  173
  242
  323
  414
  517
  630
  755
  890
  1,036
  1,193
  1,359
  1,536
  1,722
  1,918
  2,123
  2,337
  2,561
  2,794
  3,037
  3,289
  3,552
  3,825
  4,109
  4,403
  4,710
Maintenance CAPEX, $m
  0
  -1
  -1
  -2
  -3
  -4
  -5
  -6
  -7
  -9
  -11
  -13
  -15
  -18
  -20
  -23
  -27
  -30
  -34
  -37
  -41
  -46
  -50
  -54
  -59
  -64
  -69
  -74
  -80
  -86
  -92
New CAPEX, $m
  0
  -4
  -5
  -6
  -8
  -9
  -11
  -13
  -15
  -17
  -19
  -21
  -23
  -25
  -27
  -29
  -30
  -32
  -34
  -36
  -37
  -39
  -41
  -43
  -44
  -46
  -48
  -50
  -52
  -54
  -56
Cash from investing activities, $m
  0
  -5
  -6
  -8
  -11
  -13
  -16
  -19
  -22
  -26
  -30
  -34
  -38
  -43
  -47
  -52
  -57
  -62
  -68
  -73
  -78
  -85
  -91
  -97
  -103
  -110
  -117
  -124
  -132
  -140
  -148
Free cash flow, $m
  -72
  -59
  -19
  15
  53
  100
  157
  224
  301
  388
  487
  596
  717
  848
  989
  1,141
  1,302
  1,474
  1,654
  1,845
  2,044
  2,253
  2,470
  2,697
  2,933
  3,179
  3,435
  3,701
  3,977
  4,264
  4,563
Issuance/(repayment) of debt, $m
  -1
  -57
  34
  43
  54
  65
  77
  90
  103
  117
  131
  145
  158
  172
  185
  198
  211
  223
  235
  247
  259
  271
  283
  294
  306
  319
  331
  344
  358
  372
  386
Issuance/(repurchase) of shares, $m
  65
  140
  17
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  63
  83
  51
  43
  54
  65
  77
  90
  103
  117
  131
  145
  158
  172
  185
  198
  211
  223
  235
  247
  259
  271
  283
  294
  306
  319
  331
  344
  358
  372
  386
Total cash flow (excl. dividends), $m
  -9
  25
  32
  58
  107
  165
  234
  313
  404
  505
  618
  741
  875
  1,020
  1,174
  1,339
  1,513
  1,697
  1,890
  2,092
  2,303
  2,523
  2,753
  2,992
  3,240
  3,498
  3,766
  4,045
  4,335
  4,636
  4,949
Retained Cash Flow (-), $m
  -119
  -140
  -17
  -5
  -6
  -7
  -9
  -10
  -11
  -13
  -15
  -16
  -18
  -19
  -21
  -22
  -23
  -25
  -26
  -27
  -29
  -30
  -31
  -33
  -34
  -35
  -37
  -38
  -40
  -41
  -43
Prev. year cash balance distribution, $m
 
  67
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  -49
  15
  53
  101
  158
  225
  303
  392
  492
  603
  725
  858
  1,001
  1,154
  1,317
  1,490
  1,672
  1,864
  2,064
  2,274
  2,493
  2,721
  2,959
  3,206
  3,463
  3,729
  4,007
  4,295
  4,594
  4,906
Discount rate, %
 
  7.00
  7.35
  7.72
  8.10
  8.51
  8.93
  9.38
  9.85
  10.34
  10.86
  11.40
  11.97
  12.57
  13.20
  13.86
  14.55
  15.28
  16.04
  16.85
  17.69
  18.57
  19.50
  20.48
  21.50
  22.58
  23.70
  24.89
  26.13
  27.44
  28.81
PV of cash for distribution, $m
 
  -46
  13
  43
  74
  105
  135
  162
  185
  203
  215
  221
  221
  215
  203
  188
  169
  149
  128
  107
  88
  70
  54
  41
  30
  21
  15
  10
  6
  4
  2
Current shareholders' claim on cash, %
  100
  50.0
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6
  18.6

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

FINANCIAL RATIOS  of  Amarin ADR (AMRN)

Valuation Ratios
P/E Ratio -12.4
Price to Sales 8.2
Price to Book -118.8
Price to Tangible Book
Price to Cash Flow -14.9
Price to Free Cash Flow -14.9
Growth Rates
Sales Growth Rate 58.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 3
Current Ratio 0
LT Debt to Equity -944.4%
Total Debt to Equity -1288.9%
Interest Coverage -3
Management Effectiveness
Return On Assets -39.3%
Ret/ On Assets - 3 Yr. Avg. -40.3%
Return On Total Capital -74.8%
Ret/ On T. Cap. - 3 Yr. Avg. -63.4%
Return On Equity 125.5%
Return On Equity - 3 Yr. Avg. 107.9%
Asset Turnover 0.8
Profitability Ratios
Gross Margin 73.8%
Gross Margin - 3 Yr. Avg. 67.6%
EBITDA Margin -44.6%
EBITDA Margin - 3 Yr. Avg. -86.8%
Operating Margin -50.8%
Oper. Margin - 3 Yr. Avg. -92.2%
Pre-Tax Margin -58.5%
Pre-Tax Margin - 3 Yr. Avg. -103.9%
Net Profit Margin -66.2%
Net Profit Margin - 3 Yr. Avg. -103.4%
Effective Tax Rate -13.2%
Eff/ Tax Rate - 3 Yr. Avg. -1.8%
Payout Ratio 0%

AMRN stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the AMRN stock intrinsic value calculation we used $130 million for the last fiscal year's total revenue generated by Amarin ADR. The default revenue input number comes from 2016 income statement of Amarin ADR. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our AMRN stock valuation model: a) initial revenue growth rate of 42.4% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 7%, whose default value for AMRN is calculated based on our internal credit rating of Amarin ADR, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Amarin ADR.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of AMRN stock the variable cost ratio is equal to 43.8%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $147 million in the base year in the intrinsic value calculation for AMRN stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 9.3% for Amarin ADR.

Corporate tax rate of 27% is the nominal tax rate for Amarin ADR. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the AMRN stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for AMRN are equal to 6.9%.

Life of production assets of 9 years is the average useful life of capital assets used in Amarin ADR operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for AMRN is equal to 2.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $-9 million for Amarin ADR - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 274.314 million for Amarin ADR is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Amarin ADR at the current share price and the inputted number of shares is $1.1 billion.

RELATED COMPANIES Price Int.Val. Rating
TEVA Teva Pharmaceu 20.70 42.97  str.buy
ABBV AbbVie 104.64 30.60  str.sell
AZN AstraZeneca AD 35.44 26.66  sell
GSK GlaxoSmithKlin 38.20 42.07  hold
IONS Ionis Pharmace 50.22 1.06  str.sell

COMPANY NEWS

▶ 3 Growth Stocks to Own in 2018   [10:00AM  Motley Fool]
▶ ETFs with exposure to Amarin Corp. Plc : November 6, 2017   [Nov-06-17 11:03AM  Capital Cube]
▶ Amarin reports 3Q loss   [06:29AM  Associated Press]
▶ ETFs with exposure to Amarin Corp. Plc : October 23, 2017   [Oct-23-17 10:19AM  Capital Cube]
▶ ETFs with exposure to Amarin Corp. Plc : October 10, 2017   [Oct-10-17 10:58AM  Capital Cube]
▶ Amarin to Present at Cantor Global Healthcare Conference   [Sep-20-17 04:30PM  GlobeNewswire]
▶ ETFs with exposure to Amarin Corp. Plc : August 31, 2017   [Aug-31-17 05:12PM  Capital Cube]
▶ Amarin reports 2Q loss   [Aug-02-17 10:55PM  Associated Press]
▶ ETFs with exposure to Amarin Corp. Plc : June 27, 2017   [Jun-27-17 02:51PM  Capital Cube]
▶ Opening Bell, June 13, 2017   [Jun-13-17 09:29AM  CNBC Videos]
▶ Today's Bell Ringer, June 13, 2017   [09:15AM  CNBC Videos]
▶ ETFs with exposure to Amarin Corp. Plc : June 2, 2017   [Jun-02-17 01:50PM  Capital Cube]
▶ 3 Healthcare Stocks for Savvy Investors   [May-24-17 03:46PM  Motley Fool]
▶ ETFs with exposure to Amarin Corp. Plc : May 22, 2017   [May-22-17 01:20PM  Capital Cube]
▶ ETFs with exposure to Amarin Corp. Plc : May 11, 2017   [May-11-17 04:06PM  Capital Cube]
▶ Amarin reports 1Q loss   [05:06AM  Associated Press]
▶ ETFs with exposure to Amarin Corp. Plc : April 26, 2017   [Apr-26-17 03:04PM  Capital Cube]
▶ ETFs with exposure to Amarin Corp. Plc : April 7, 2017   [Apr-07-17 03:46PM  Capital Cube]
▶ 3 Stocks That Could Make You Rich   [Mar-28-17 12:24PM  Motley Fool]
▶ 3 Stocks That Could Make You Rich   [12:24PM  at Motley Fool]
▶ 4 Biotech Stocks With Jaw-Dropping Growth Potential   [Mar-21-17 08:09AM  Motley Fool]
▶ Amarin reports 4Q loss   [06:21AM  Associated Press]
▶ 1 Reason Amarin's Stock Skyrocketed in 2016   [Jan-10-17 09:39AM  at Motley Fool]
Financial statements of AMRN
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.